Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Whistleblower Letter Released At Sebelius Confirmation Hearing

This article was originally published in The Gray Sheet

Executive Summary

Nine FDA scientists urge "sweeping measures" and harsh disciplinary action within the agency in an April 2 1letter to President Obama that was publicly disclosed during a confirmation hearing for the likely next secretary of the Department of Health and Human Services

You may also be interested in...



Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?

FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review

Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?

FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review

FDA Refines Requirements For Computer-Aided Detection

FDA published two draft guidance documents Oct. 21 to help firms through 510(k) or PMA submissions for computer-aided detection tools; on the following day, the agency announced an upcoming panel meeting on the topic

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel